Search
Celiprolol
go.drugbank.com/drugs/DB04846ApprovedInvestigationalWithdrawnThis study demonstrated decreased incidence of arterial rupture or dissection (a specific type of arterial rupture in which the layers of the vessel separate prior to complete failure of the artery wall … Celiprolol is not approved for use by the FDA in the treatment of vascular Ehlers–Danlos syndrome.
Synonyms: RS)-N'-{3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-N,N-diethylureaInfluenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14407ApprovedInvestigationalInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Efluelda Tetra Injektionssuspension in einer Fertigspritze, VAXİGRİP 0,5 ML IM/SC ENJEKSİYON İÇİN SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR , 10 ADETSiltuximab
go.drugbank.com/drugs/DB09036ApprovedInvestigationalSiltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. … It is administered as a 1 hour intravenous infusion every 3 weeks.
Dihydrostreptomycin
go.drugbank.com/drugs/DB11512ApprovedVet approvedWithdrawnDihydrostreptomycin is an aminoglycoside antibiotic. In humans, the use of dihydrostreptomycin has been associated with ototoxicity. … The FDA withdrew its approval for the use of all drug products containing dihydrostreptomycin sulfate.[L43942]
Synonyms: N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-a-L-glucopyranosyl]-3-C-(hydroxymethyl)-a-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine, N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-α-L-glucopyranosyl]-3-C-(hydroxymethyl)-α-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidineCeforanide
go.drugbank.com/drugs/DB00923ApprovedCeforanide is administered parenterally. It has a longer elimination half-life than any currently available cephalosporin. … Its activity is very similar to that of cefamandole, another second-generation cephalosporin antibiotic, except that ceforanide is less active against most gram-positive organisms.
Tetrachlorodecaoxide
go.drugbank.com/drugs/DB05389ApprovedThe Corporation has commenced a Phase II clinical trial in an effort to demonstrate the efficacy of WF10 in combination with Xeloda (capecitabine) in the treatment of pancreatic cancer. … WF10 is a chlorite-based, immunomodulating drug is developed by Nuvo Research Inc. Certain preclinical evidence and clinical pilot data suggest that WF10 may be effective in treating certain cancers.
Categories: Compounds used in a research, industrial, or household settingStreptococcus pneumoniae type 3 capsular polysaccharide antigen
go.drugbank.com/drugs/DB10321ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 3 capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 3 of *Streptococcus pneumoniae*.
Mixtures: PNEUMOVAX 23 Injektionslösung in einer Fertigspritze, PNEUMOVAX 23 Injektionslösung in einer DurchstechflaschePitavastatin
go.drugbank.com/drugs/DB08860ApprovedInvestigational[A181087, A181406] Pitavastatin and other drugs from the statin class of medications including [atorvastatin], [pravastatin], [rosuvastatin], [fluvastatin], and [lovastatin] are considered first-line … were found in clinical studies to result in a 45.8% to 54.6% decrease in LDL cholesterol levels.
Technetium Tc-99m oxidronate
go.drugbank.com/drugs/DB09139ApprovedWithdrawnA radiopharmaceutical is defined as a medicinal formulation containing radioisotopes that are used in major clinical areas for diagnosis and/or therapy. … [L1140] It was developed by Mallinkrodt nuclear and FDA approved on February 18, 1981.
Viltolarsen
go.drugbank.com/drugs/DB15005ApprovedInvestigationalis contingent on further verification in confirmatory trials. … [A218176] Viltolarsen was granted accelerated FDA approval on August 12, 2020, based on data showing an increase in dystrophin levels in skeletal muscle of patients treated with viltolarsen; this approval